New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 14, 2013
2013 Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 14-16 with webcasted presentations to begin on October 14 at 11 am; not all presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
September 30, 2015
05:33 EDTBTXHeraeus Medical and BioTime subsidiary enter into exclusive worldwide agreement
Heraeus Medical GmbH and BioTime announced that BioTime's subsidiary OrthoCyte Corporation and Heraeus Medical have entered into exclusive development and worldwide licensing agreements for the development of innovative bone grafting therapies based on the use of BioTime's proprietary PureStem human embryonic progenitor cell technology. Under the terms of the development agreement, Heraeus Medical would make an initial $1M upfront payment to OrthoCyte, and additional payments upon OrthoCyte's attainment of certain product development milestones, and Heraeus will fund all ongoing product development activities through IND submission. Heraeus Medical will be responsible for worldwide sales if a product is successfully developed, can be demonstrated through clinical trials to be safe and effective, and receives regulatory approval for marketing. OrthoCyte will be responsible for product development and initially for manufacturing. Pursuant to the terms of the license agreement, OrthoCyte has licensed certain technology to Heraeus, and Heraeus has licensed certain technology to OrthoCyte. The license grant by OrthoCyte to Heraeus is exclusive and worldwide in the field of bone grafting for all osteoskeleton diseases and injuries, except oral maxillofacial. The license grant by Heraeus to OrthoCyte is exclusive and worldwide in all other fields. Pursuant to the license agreement, each of Heraeus and OrthoCyte will pay certain specified royalties to each other based on their respective net sales of the product developed under the development agreement.
05:27 EDTMBLTYMesoblast says Phase 2 trial shows lead product candidate effective
Subscribe for More Information
September 29, 2015
11:11 EDTCELGStocks with call strike movement; CELG GILD
Subscribe for More Information
08:33 EDTBLUEAlexandria Real Estate announces bluebird bio executed lease
Alexandria Real Estate (ARE) Equities announced that bluebird bio (BLUE) executed a 10-year lease for approximately 253,000 rentable square feet at 60 Binney Street at the Alexandria Center at Kendall Square campus. The lease encompasses the entire 60 Binney Street building with the exception of a ground-floor retail suite. With the relocation of its headquarters to 60 Binney Street, bluebird bio, a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, will be expanding its presence in Cambridge to support the company's continued growth. The 60 Binney Street project, which is targeting LEED Gold Certification, is expected to be delivered in late 2016.
September 28, 2015
10:00 EDTFCSCOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Aratana Therapeutics (PETX) downgraded to Hold from Buy at Craig-Hallum... Astoria Financial (AF) downgraded to Neutral from Buy at Guggenheim... Cosan (CZZ) downgraded to Neutral from Buy at BofA/Merrill... Cummins (CMI) downgraded to Hold from Buy at BB&T... DSW (DSW) downgraded to Neutral from Buy at B. Riley... Fibrocell Science (FCSC) downgraded to Neutral from Outperform at Wedbush... Galapagos NV (GLPG) downgraded to Neutral from Outperform at Credit Suisse... Heritage Commerce (HTBK) downgraded to Hold from Buy at Sandler O'Neill... International Flavors (IFF) downgraded to Equal Weight from Overweight at Barclays... MINDBODY (MB) downgraded to Equal Weight from Overweight at Morgan Stanley... MercadoLibre (MELI) downgraded to Sell from Neutral at Citi... Navistar (NAV) downgraded to Neutral from Accumulate at Global Hunter... Premiere Global (PGI) downgraded to Equal Weight from Overweight at Stephens... Qorvo (QRVO) downgraded to Sector Weight from Overweight at Pacific Crest... Snyder's-Lance (LNCE) downgraded to Hold from Buy at BB&T... Stryker (SYK) downgraded on M&A sentiment shift at Needham... TD Ameritrade (AMTD) downgraded to Market Perform from Outperform at Wells Fargo... Telecom Argentina (TEO) downgraded to Sell from Neutral at Goldman... Varian Medical (VAR) downgraded to Sell from Neutral at Goldman... Verastem (VSTM) downgraded to Neutral from Buy at Roth Capital... Vodacom (VDMCY) downgraded to Hold from Buy at Deutsche Bank.
08:04 EDTBTXBioTime, Cell Cure Neurosciences receive FDA fast track designation for OpRegen
Subscribe for More Information
07:52 EDTGSKIIR Holdings to hold a conference
Subscribe for More Information
07:18 EDTFCSCFibrocell Science downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
September 27, 2015
16:58 EDTGSKGlaxoSmithKline, Theravance report Phase 3 data on Anoro Ellipta for COPD
Subscribe for More Information
September 25, 2015
17:10 EDTBTXBioTime to sell $20.7M of common stock in registered direct offering
BioTime announced that it has agreed to sell up to $20.7M of its common shares in a registered direct offering to select investment funds in Israel that hold shares of companies that are included within certain stock indexes of the Tel Aviv Stock Exchange. The price per share will be determined with reference to the closing price of BioTime common shares on the TASE on the trading day immediately preceding the first day on which BioTime common shares enter the TASE stock indexes. The sale of the common shares is expected to close on or about October 1, 2015, subject to the satisfaction of customary closing conditions. The amount of aggregate proceeds from the sale and the total number of shares sold will depend upon the market price of BioTime common shares and the number of BioTime common shares the investment funds need to purchase from BioTime to put their portfolios in balance with the TASE stock indexes that they track. BioTime will pay Union Underwriting & Finances Ltd an investment banking fee in the amount of 1% of the aggregate purchase price of the common shares sold.
16:17 EDTCELGOn The Fly: Top stock stories for Friday
Stocks opened with sharp gains the day after Fed Chair Janet Yellen gave some clarity to the market by suggesting the Fed will most likely raise interest rates by the end of the year. During afternoon trading, the news flow slowed and the volume lightened on the buy side, leaving the sellers with the upper hand. The Nasdaq was the first index to move into negative territory, led by broad weakness in biotech stocks, while the Dow was helped to stay in the green by a big post-earnings move higher in Nike (NKE). The averages limped into the close, leaving the market with an interesting set-up to begin next week. Outside of stock news, it was certainly a headline packed day, as Speaker of the House John Boehner announced that he will resign at the end of October, Chinese President Xi Jinping continued his U.S. visit and Pope Francis addressed the United Nations while spending a second day in New York City. ECONOMIC EVENTS: In the U.S., the third estimate of second quarter GDP showed the economy grew 3.9% quarter-over-quarter, versus expectations for the GDP growth estimate to stay at 3.7%. Personal consumption in Q2 is now believed to have grown 3.6%, up from the prior estimate of 3.1%. The final University of Michigan consumer sentiment reading for September came in at 87.2, which was down from August's 91.9 but above the expected 86.2 reading... Federal Reserve Chair Janet Yellen said during a speech at UMass Amherst last night that the central bank remains inclined to hike rates this year. Yellen's remarks were incrementally hawkish, but welcomed by the market, since they helped clarify the message the Fed delivered a week ago. Of note, the Fed chair paused multiple times toward the end of her speech and received medical attention afterward, but returned to her regular schedule later in the evening, with the bank explaining that Yellen was dehydrated after a long day but was otherwise fine. COMPANY NEWS: Nike jumped $10.23, or 8.9%, to $125.02 after Thursday night's report of better than expected earnings and futures orders prompted numerous price target hikes at Street research firms. Additionally, Sterne Agee upgraded Nike to Buy from Neutral, saying it thinks the company is benefiting from its "global grass roots engagement with its customers," which enables it to meet its customers' needs and determine to what extent it can raise prices. The firm, which thinks that the company is continuing to gain share, has a $150 price target on the athletic gear giant... Biotech stocks, which were already having a bad week, ended the week on a down note, as the iShares NASDAQ Biotechnology Index (IBB) fell 4.9%, giving it a weekly decline of about 13%. Among the biggest large-cap losers in the space were Vertex (VRTX), which fell 7%, Regeneron (REGN), which dropped 6% and Celgene (CELG), which slid 4.8%. MAJOR MOVERS: Among the notable gainers was Jabil Circuit (JBL), which advanced $2.38, or 12.2%, to $21.88 after it reported higher than expected earnings and gave guidance for its November quarter that was significantly above expectations. Also higher was Cirrus Logic (CRUS), which gained $3.90, or 14.4%, to $31.03 after tear downs of Apple's (AAPL) iPhone 6S and 6S Plus led analysts to conclude that the chipmaker appears poised to obtain more revenue from the new devices than from the previous generation of the market-leading smartphone. Among the noteworthy losers was Finish Line (FINL), which fell $4.86, or 19.6%, to $19.91 after reporting second quarter revenue that missed expectations and saying it expects adjusted earnings this fiscal year to increase in a low single to mid single digits percentage from last year. Also lower following its earnings report was smartphone and software maker BlackBerry (BBRY), which slid 7.68% to $6.49 after the company posted a second quarter loss that was steeper than analysts expected. BlackBerry also confirmed press reports that it plans to launch a new phone that uses Google's (GOOG) Android operating system instead of its own proprietary BB10 OS. Shares of Aratana Therapeutics (PETX), which dropped $6.81, or 38.97%, to $10.68 after the company said that, based on "mixed clinical and scientific results," it does not believe that canine lymphoma products AT-004 and AT-005 in their current, first-generation forms will capture the desired lymphoma market opportunity. INDEXES: The Dow rose 113.35, or 0.7%, to 16,314.67, the Nasdaq fell 47.98, or 1.01%, to 4,686.50, and the S&P 500 added/slipped 0.90, or 0.05%, to 1,931.34.
11:35 EDTBLUEbluebird bio management to meet with Maxim
5:30 pm Cocktails, followed by 6pm Group dinner with management will be held in New York on September 30 hosted by Maxim.
08:04 EDTFCSCFibrocell, Intrexon provide update for RDEB treatment
Fibrocell (FCSC) and Intrexon (XON) provided an update on the status of the previously filed Investigational New Drug application for FCX-007, Fibrocell's orphan gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa, including feedback from the U.S. Food and Drug Administration on the IND. The FDA's feedback related to the proposed Phase I/II clinical trial protocol and the areas of CMC and toxicology. With respect to toxicology, a hybrid pharmacology/toxicology study based on the injection of FCX-007 in RDEB human skin that was xenografted onto SCID mice was included in the IND and showed no signs of toxicity. However, the FDA has now requested that Fibrocell execute a toxicology-specific study in which FCX-007 will be injected in non-grafted SCID mice. The new toxicology study is targeted to initiate in the fourth quarter of 2015. Fibrocell expects to amend the IND in response to the FDA's feedback and to include data from the new toxicology study in the first quarter of 2016.
07:22 EDTCELGEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
05:21 EDTCELGCelgene's VIDAZA receives positive CHMP opinion
Subscribe for More Information
September 24, 2015
11:24 EDTGSKGlaxoSmithKline receives positive CHMP opinion in Europe for Nucala
Subscribe for More Information
05:24 EDTGSKGlaxoSmithKline and Theravance intend to file Relvar Ellipta for COPD in Japan
Subscribe for More Information
September 23, 2015
13:09 EDTGSKEU could green light GlaxoSmithKline's new asthma drug this week, Reuters says
Subscribe for More Information
07:53 EDTBAXUBS medical supplies & devices analyst holds an analyst/industry conference call
Subscribe for More Information
05:32 EDTGSKViiV Healthcare announces Triumeq Phase IIIb study met primary endpoint
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use